Search results
Showing 1401 to 1450 of 2052 results for work
Early value assessment (EVA) guidance on guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of anxiety or low mood.
For which people with impetigo are antiseptics as effective as antibiotics?
A faster recovery is also likely to mean less time off school, nursery or work. It was not clear in the evidence reviewed if impetigo...
Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services.
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]
In development Reference number: GID-TA10822 Expected publication date: TBC
In development Reference number: GID-TA11585 Expected publication date: TBC
Discontinued Reference number: GID-TAG437
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
In development Reference number: GID-TA11569 Expected publication date: TBC
In development Reference number: GID-TA11074 Expected publication date: TBC
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)
Evidence-based recommendations on carfilzomib (Kyprolis) with dexamethasone and lenalidomide (Revlimid) for previously treated multiple myeloma in adults.
Evidence-based recommendations on mifamurtide (Mepact) for treating osteosarcoma in people aged 2 to 30 years.
Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]
Discontinued Reference number: GID-TA11109
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]
Discontinued Reference number: GID-HST10007
In development Reference number: GID-TA11146 Expected publication date: TBC
Benralizumab for previously treated severe nasal polyps [ID1659]
In development Reference number: GID-TA10818 Expected publication date: TBC
Discontinued Reference number: GID-TA10841
In development Reference number: GID-HST10020 Expected publication date: TBC
Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]
Discontinued Reference number: GID-TA10416
Discontinued Reference number: GID-TA10566
Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]
Discontinued Reference number: GID-TA10151
Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)
Discontinued Reference number: GID-TA10527
Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]
Discontinued Reference number: GID-TAG511
Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)
Discontinued Reference number: GID-TA10180
This quality standard covers improving the quality of the patient experience for people who use adult NHS services. It describes high-quality care in priority areas for improvement.
View quality statements for QS15Show all sections
Sections for QS15
- Quality statements
- Quality statement 1: Empathy, dignity and respect
- Quality statement 2: Contacts for ongoing care
- Quality statement 3: Information exchange
- Quality statement 4: Individualised care
- Quality statement 5: Preferences for sharing information
- Quality statement 6: Decision making
- Update information
This quality standard covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It describes high-quality care in priority areas for improvement. It does not cover areas of national policy, such as the UK Bacillus Calmette-Guérin (BCG) immunisation programme.
View quality statements for QS141Show all sections
Sections for QS141
- Quality statements
- Quality statement 1: Latent tuberculosis testing for people from high-incidence countries
- Quality statement 2: Latent tuberculosis testing for adults with HIV
- Quality statement 3: Rapid diagnosis of pulmonary tuberculosis
- Quality statement 4: Assessment
- Quality statement 5: Directly observed therapy
- Quality statement 6: Accommodation
- Update information
Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]
Discontinued Reference number: GID-TA10081
Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]
Discontinued Reference number: GID-TA10088
In development Reference number: GID-TA10696 Expected publication date: TBC
Discontinued Reference number: GID-TAG409
Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]
Discontinued Reference number: GID-TA10295
Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer [ID1357]
Discontinued Reference number: GID-TA10322
Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.
Degarelix for treating advanced hormone-dependent prostate cancer (TA404)
Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.
Discontinued Reference number: GID-TA10202
Nelarabine for treating refractory T-cell lymphoblastic non-Hodgkin's lymphoma [ID1044]
Discontinued Reference number: GID-TA10087
In development Reference number: GID-TA10747 Expected publication date: TBC
Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]
Discontinued Reference number: GID-TA10164
Generalised anxiety disorder and panic disorder in adults: management (CG113)
This guideline covers the care and treatment of people aged 18 and over with generalised anxiety disorder (chronic anxiety) or panic disorder (with or without agoraphobia or panic attacks). It aims to help people achieve complete relief of symptoms (remission), which is associated with better functioning and a lower likelihood of relapse.
Ofatumumab for treating relapsing multiple sclerosis (TA699)
Evidence-based recommendations on ofatumumab (Kesimpta) for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features.
Evidence-based recommendations on ruxolitinib (Jakavi). This drug is for adults with disease-related splenomegaly or symptoms caused by primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only if they have intermediate-2 or high-risk disease.
Evidence-based recommendations on nivolumab (Opdivo) for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy in adults.
In development Reference number: GID-TA10391 Expected publication date: TBC
Read the biographies for all members of the NICE antimicrobial evaluation committee.
Read the biographies for all members of the NICE antimicrobial evaluation committee.
In development Reference number: GID-TA11351 Expected publication date: TBC
NICE has developed a medtech innovation briefing (MIB) on StoneChecker for kidney stone evaluation .
NICE has developed a medtech innovation briefing (MIB) on AI technologies for detecting diabetic retinopathy .
Vosoritide for treating achondroplasia in people 4 months and over [ID6488]
In development Reference number: GID-TA11528 Expected publication date: TBC
Nintedanib for treating interstitial lung disease caused by systemic sclerosis [ID1420]
Discontinued Reference number: GID-TA10427
Path Finder for freezing of gait in people with Parkinson's disease (MIB170)
NICE has developed a medtech innovation briefing (MIB) on Path Finder for freezing of gait in people with Parkinson’s disease .
Esketamine nasal spray for treatment-resistant depression (TA854)
Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.